Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- In its ongoing R&D reorganization, Biogen Inc (NASDAQ:BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ:DNLI).
- Before the planned revisions, the BIIB122 development program encompassed the following:
- The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022.
- The Phase 3 LIGHTHOUSE study in participants with Parkinson’s disease related to LRRK2 mutations commenced in September 2022 and was slated for completion in 2031. Biogen said the decision was made considering the study’s “complexity, including the long timeline.”
- Related: Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs.
- “These modifications are not based on any safety or efficacy data from studies of BIIB122,” the company said. “Denali and Biogen have a strategic collaboration to jointly develop and commercialize small molecule inhibitors of LRRK2 and remain committed to advancing the development of BIIB122.”
- Biogen and Denali said they are now focusing on the ongoing Phase 2b LUMA study in patients with early-stage Parkinson’s.
- This trial will now also enroll patients with an LRRK2 mutation in addition to the previously eligible trial population, and patients enrolled in the LIGHTHOUSE study will be given a chance to join the LUMA study.
- In August 2020, Biogen and Denali signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
- Biogen shelled out $560 million and $465 million equity investment.
- Price Action: DNLI shares closed down 3.36% at $30.46 on Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!